Insmed Announces Proposed $500 Million Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Insmed (INSM) PT Raised to $67 at Stifel
May 30, 2024 4:35 PM EDTStifel analyst Stephen D. Willey raised the price target on Insmed (NASDAQ: INSM) to $67.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "We believe topline P3 ASPEN results will establish brensocatib as the first-approved, standardof-care therapy in NCFBE and meaningfully improve investor... More
Insmed (INSM) PT Raised to $58 at UBS
May 29, 2024 5:37 AM EDTUBS analyst Trung Huynh raised the price target on Insmed (NASDAQ: INSM) to $58.00 (from $46.00) while maintaining a Buy rating.
The analyst comments "Management believes from now through the regulatory review process, the path is noncontroversial given the strength of data presented... More
Insmed (INSM) PT Raised to $68 at Truist Securities
May 29, 2024 5:30 AM EDTTruist Securities analyst Nicole Germino raised the price target on Insmed (NASDAQ: INSM) to $68.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "With greater confidence into brensocatib potential approval following positive ASPEN results today and supported by our KOL call last... More
Insmed (INSM) PT Raised to $54 at Wolfe Research
May 29, 2024 5:25 AM EDTWolfe Research analyst Andy Chen raised the price target on Insmed (NASDAQ: INSM) to $54.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "How to think about stock valuation, even assuming a capital raise? The previous stock in the mid-$20s implied POS... More
Insmed (INSM) PT Raised to $62 at BofA Securities
May 29, 2024 5:08 AM EDTBofA Securities analyst Jason Zemansky raised the price target on Insmed (NASDAQ: INSM) to $62.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "This mornings positive readout for novel DPP-1 inhibitor brenso (see report: our initial takes on the data) represents a... More
